Valneva SE
PAR:VLA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Valneva SE
Operating Income
Valneva SE
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Valneva SE
PAR:VLA
|
Operating Income
-€81.6m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-15%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Operating Income
-€53.6m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-12%
|
|
|
Inventiva SA
PAR:IVA
|
Operating Income
-€141m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
|
Cellectis SA
PAR:ALCLS
|
Operating Income
-$33.1m
|
CAGR 3-Years
28%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-1%
|
|
|
DBV Technologies SA
PAR:DBV
|
Operating Income
-$146.9m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-12%
|
|
|
Abivax SA
PAR:ABVX
|
Operating Income
-€246.1m
|
CAGR 3-Years
-69%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
-30%
|
|
Valneva SE
Glance View
Valneva SE is a biotech company. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 722 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
See Also
What is Valneva SE's Operating Income?
Operating Income
-81.6m
EUR
Based on the financial report for Dec 31, 2025, Valneva SE's Operating Income amounts to -81.6m EUR.
What is Valneva SE's Operating Income growth rate?
Operating Income CAGR 10Y
-15%
Over the last year, the Operating Income growth was -6%. The average annual Operating Income growth rates for Valneva SE have been 10% over the past three years , -23% over the past five years , and -15% over the past ten years .
